✦ LIBER ✦

Lack of emerging resistance mutations in 467 HBeAg− and HBeAg+ patients with chronic hepatitis B receiving Adefovir Dipivoxil for 48 weeks

✍ Scribed by Huiling Yang; Christopher Westland; William Delaney IV; Craig Gibbs; Michael Miller; John Fry; Carol Brosgart; Shelly Xiong

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

508 Clinical profile of HBeAg- chronic h

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 102 KB

1159 Lack of ethnic differences in respo

✍ LIM, S; MARCELLIN, P; TASSOPOULOS, N; HADZIYANNIS, S; CHANG, T; TONG, M; SIEVERT 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

Resistance surveillance of HBEAG— chroni

✍ S. Xiong; H. Yang; C.E. Westland; W.E. Delaney IV; D. Colledge; A. Bartholomeusz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

1141 Complete genotypic and phenotypic a

✍ YANG, H; WESTLAND, C; DELANEYIV, W; ANGUS, P; LOCARNINI, S; KITIS, G; WULFSOHN, 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Efficacy and safety of telbivudine plus

✍ Lu, Jia-Jie; Liu, Kai; Ma, Yuan-Ji; Wang, Juan; Chen, En-Qiang; Tang, Hong 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

Efficacy of 96 weeks adefovir dipivoxil

✍ L. Zhuang; J. You; L. Kong; H. Lei; R.-D. Yang; X. Zhang; Q.-Q. Wang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 84 KB